SG11201806496SA - Antigen binding proteins that bind pd-l1 - Google Patents
Antigen binding proteins that bind pd-l1Info
- Publication number
- SG11201806496SA SG11201806496SA SG11201806496SA SG11201806496SA SG11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA SG 11201806496S A SG11201806496S A SG 11201806496SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bind
- january
- pct
- rule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662288912P | 2016-01-29 | 2016-01-29 | |
| PCT/US2017/015429 WO2017132562A1 (fr) | 2016-01-29 | 2017-01-27 | Protéines de liaison à l'antigène se liant à pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806496SA true SG11201806496SA (en) | 2018-08-30 |
Family
ID=59386438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806496SA SG11201806496SA (en) | 2016-01-29 | 2017-01-27 | Antigen binding proteins that bind pd-l1 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10118963B2 (fr) |
| EP (1) | EP3408400B1 (fr) |
| JP (3) | JP6883590B2 (fr) |
| KR (1) | KR20190026642A (fr) |
| CN (2) | CN116333124A (fr) |
| AU (1) | AU2017212717B2 (fr) |
| BR (1) | BR112018015480A2 (fr) |
| CA (1) | CA3013051A1 (fr) |
| CL (1) | CL2018002034A1 (fr) |
| EA (1) | EA037855B1 (fr) |
| IL (1) | IL260846B2 (fr) |
| MX (2) | MX2018009228A (fr) |
| PH (1) | PH12018501611A1 (fr) |
| SG (1) | SG11201806496SA (fr) |
| TW (1) | TWI760323B (fr) |
| WO (1) | WO2017132562A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220084444A (ko) * | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CA3013051A1 (fr) | 2016-01-29 | 2017-08-03 | Heyue Zhou | Proteines de liaison a l'antigene se liant a pd-l1 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
| US20200407447A1 (en) * | 2018-03-22 | 2020-12-31 | Keires Ag | Antagonistic pd-1, pd-l1 and lag-3 binding proteins |
| CN110869390B (zh) | 2018-04-09 | 2021-05-11 | 上海原能细胞医学技术有限公司 | 抗pd-l1抗体及其用途 |
| WO2019227490A1 (fr) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions et procédés d'imagerie |
| BR112020023505A2 (pt) | 2018-06-01 | 2021-03-30 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Composições e usos das mesmas para tratamento de doença ou condição |
| SG11202101757QA (en) * | 2018-08-20 | 2021-03-30 | 1Globe Biomedical Co Ltd | Novel cancer immunotherapy antibody compositions |
| WO2020215020A1 (fr) * | 2019-04-18 | 2020-10-22 | Qlsf Biotherapeutics Inc. | Anticorps anti-pd-l1 humanisés |
| KR20220012856A (ko) * | 2019-08-29 | 2022-02-04 | 레메젠 코, 리미티드 | 항 ｐｄ―ｌ１ 항체 및 그의 용도 |
| US20230338574A1 (en) | 2020-09-02 | 2023-10-26 | Mayo Foundation For Medical Education And Research | Antibody-nanoparticle complexes and methods for making and using the same |
| JP2023552694A (ja) | 2020-11-16 | 2023-12-19 | イミューンオンシア セラピューティクス インコーポレイテッド | 免疫抗がん剤に対する治療反応性を予測するためのバイオマーカーおよびその用途 |
| WO2022235127A1 (fr) | 2021-05-07 | 2022-11-10 | 주식회사 이뮨온시아 | Anticorps bispécifique se liant spécifiquement à cd47 et pd-l1 |
| WO2022261262A1 (fr) | 2021-06-09 | 2022-12-15 | Sorrento Therapeutics, Inc. | Méthode de traitement du cancer par administration d'un agent thérapeutique anti-pd-1 ou anti-pd-l1 par l'intermédiaire d'un dispositif d'administration lymphatique par micro-aiguilles |
| WO2024064640A2 (fr) * | 2022-09-19 | 2024-03-28 | Sonoma Biotherapeutics, Inc. | Récepteurs antigéniques chimériques spécifiques d'un antigène citrulliné pour cibler des lymphocytes t régulateurs pour traiter l'hidradénite suppurée |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| EP0861893A3 (fr) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | Expression de haut niveau d'immunoglobulines |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| ATE225801T1 (de) | 1992-07-13 | 2002-10-15 | Bionebraska Inc | Verfahren zur modifizierung rekombinanter polypeptide |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| EP2722336A1 (fr) | 2007-06-01 | 2014-04-23 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Vaccin pour la prévention de la rechute du cancer du sein |
| US8877688B2 (en) * | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| KR20220084444A (ko) * | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| CN107892719B (zh) * | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| CA3175360C (fr) * | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Proteines de liaison a l'antigene qui se lient a pd-1 |
| US10267806B2 (en) * | 2014-04-04 | 2019-04-23 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
| CN105238762A (zh) * | 2015-10-26 | 2016-01-13 | 无锡傲锐东源生物科技有限公司 | 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用 |
| CA3013051A1 (fr) * | 2016-01-29 | 2017-08-03 | Heyue Zhou | Proteines de liaison a l'antigene se liant a pd-l1 |
-
2017
- 2017-01-27 CA CA3013051A patent/CA3013051A1/fr active Pending
- 2017-01-27 WO PCT/US2017/015429 patent/WO2017132562A1/fr active Application Filing
- 2017-01-27 EA EA201891709A patent/EA037855B1/ru unknown
- 2017-01-27 EP EP17745008.7A patent/EP3408400B1/fr active Active
- 2017-01-27 BR BR112018015480-6A patent/BR112018015480A2/pt not_active Application Discontinuation
- 2017-01-27 KR KR1020187024978A patent/KR20190026642A/ko active Search and Examination
- 2017-01-27 US US15/418,514 patent/US10118963B2/en active Active
- 2017-01-27 JP JP2018559164A patent/JP6883590B2/ja active Active
- 2017-01-27 MX MX2018009228A patent/MX2018009228A/es unknown
- 2017-01-27 AU AU2017212717A patent/AU2017212717B2/en active Active
- 2017-01-27 CN CN202210999239.9A patent/CN116333124A/zh active Pending
- 2017-01-27 CN CN201780021396.XA patent/CN109715821B/zh active Active
- 2017-01-27 SG SG11201806496SA patent/SG11201806496SA/en unknown
- 2017-02-02 TW TW106103519A patent/TWI760323B/zh active
-
2018
- 2018-07-27 CL CL2018002034A patent/CL2018002034A1/es unknown
- 2018-07-27 MX MX2022011659A patent/MX2022011659A/es unknown
- 2018-07-29 IL IL260846A patent/IL260846B2/en unknown
- 2018-07-30 PH PH12018501611A patent/PH12018501611A1/en unknown
- 2018-10-10 US US16/156,895 patent/US10919964B2/en active Active
-
2021
- 2021-01-13 US US17/148,450 patent/US11919952B2/en active Active
- 2021-03-22 JP JP2021047470A patent/JP7140867B2/ja active Active
-
2022
- 2022-04-15 JP JP2022067548A patent/JP2022095910A/ja active Pending
-
2024
- 2024-01-12 US US18/412,102 patent/US20240190959A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201903674YA (en) | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201804694SA (en) | Dual controls for therapeutic cell activation or elimination | |
| SG11201903835WA (en) | Antibodies directed against programmed death- 1 (pd-1) | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same |